Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Oncology
Erschienen in: Current Treatment Options in Oncology 2/2014

01.06.2014 | Skin Cancer (WH Sharfman, Section Editor)

Clinical Applications of Melanoma Genetics

verfasst von: Michele Gabree, MS, Devanshi Patel, MS, Linda Rodgers, MGC

Erschienen in: Current Treatment Options in Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Opinion statement

Families that have several relatives with melanoma, multiple primary melanomas in one individual, younger than average ages of melanoma onset, and/or the presence of both pancreatic cancer and melanoma may be suggestive of a hereditary melanoma syndrome and are candidates for genetic counseling and risk assessment. Genetic counseling for hereditary melanoma presents many complexities. Only a minority of hereditary melanoma cases have been attributed to a single genetic factor, CDKN2A. Both the frequency and the penetrance of CDKN2A mutations has been shown to be dependent on multiple factors. The clinical utility of genetic testing for hereditary melanoma families is debatable because CDKN2A status may not impact medical management in patients with melanoma. No standard medical management guidelines exist for families with CDKN2A mutations; however, family history of melanoma and pancreatic cancer may warrant further discussion. Clinicians should discuss the clinical and psychological implications before genetic testing. Genetic counseling and pretest education regarding melanoma risk factors provides an opportunity to increase knowledge and understanding of melanoma risk, while addressing psychological risks and concerns.
Literatur
1.
Goldstein A, Chan M, Harland M, Hayward N, Demenais F, Bishop DT, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44:99–106.PubMedCentralPubMedCrossRef
2.
Bishop DT, Demenais F, Goldstein A, Bergman W, Bishop J, Bressac-de Paillerets B, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894–903.PubMedCrossRef
3.
Leachman S, Carucci J, Kohlmann L, Banks K, Asgari M, Bergman W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61:677.e1–14.CrossRef
4.
Njauw CNJ, Kim I, Piris A, Gabree M, Taylor M, Lane AM, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7:e35295.PubMedCentralPubMedCrossRef
5.
Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst. 2013;105:1607–16.PubMedCrossRef
6.
Monnerat C, Chompret A, Kannengiesser C, Avril M, Janin N, Spatz A, et al. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer. 2007;6:453–61.PubMedCrossRef
7.
Cruz C, Teule A, Caminal J, Blanco I, Piulats J. Uveal melanoma and BRCA1/BRCA2 genes: a relationship that needs further investigation. J Clin Oncol. 2011;29:e827–9.PubMedCrossRef
8.
Curiel-Lewandrowski C, Curiel-Lewandrowski C, Speetzen L, Cranmer L, Warneke J, Loescher L. Multiple primary cutaneous melanomas in Li-Fraumeni syndrome. Arch Dermatol. 2011;147:248–50.PubMedCrossRef
9.
Goldstein A, Chan M, Harland M, Gillanders E, Hayward N, Avril M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818–28.PubMedCrossRef
10.
Bertolotto C, Lesuer F, Giuliano S, Strub T, de Lichy M, Bille K, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480:94–8.PubMedCrossRef
11.
Bradford P, Goldstein A, Tamura D, Khan S, Ueda T, Boyle J, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet. 2011;48:168–76.PubMedCentralPubMedCrossRef
12.
13.
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48.PubMed
14.
Austin MT, Xing Y, Hayes-Jordan AA, Lally KP, Cormier JN. Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg. 2013;48(11):2207–13.PubMedCrossRef
15.
Erdmann F, Lortet-Tieulen J, Schuz J, Zeeb H, Greinert R, Breitbar EW, et al. International trends in the incidence of malignant melanoma 1953-2008—are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385–400.PubMedCrossRef
16.
Gandini S, Sera F, Cattaruzz MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41(1):28–44.PubMedCrossRef
17.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60.PubMedCrossRef
18.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040–59.PubMedCrossRef
19.
20.
21.
Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003;95:806–12.PubMedCrossRef
22.••
van der Ree J, Krijnen P, Gruis N, de Snoo F, Vasen H, Putter H, et al. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. J Am Acad Dermatol. 2011;65:281–8. This study of CDKN2A phenotypes examined individuals in the Netherlands with a founder CDKN2A mutation (p16-Leiden). Consistent with other studies of CDKN2A mutation carriers, this study found younger age of onset and a greater number of individuals with multiple primary melanomas in individuals with CDKN2A mutations versus controls. They also report histological differences, including more superficial spreading and less nodular and lentiginous melanomas, in CDKN2A mutation carriers versus the control group. They conclude that their findings support that melanomas in individuals with CDKN2A mutations develop through a different pathway than later-onset, sporadic melanomas.CrossRef
23.
Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat. 2004;23(6):630.PubMedCrossRef
24.
McKenzie HA, Fung C, Becker TM, Irvine M, Mann GJ, Kefford RF, et al. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A. Hum Mutat. 2010;31(6):692–701.
25.
Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res. 2013;19(19):5320–8.
26.••
Puntervoll H, Yang X, Vetti H, Bachmann I, Avril M, Benfodda M, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet. 2013;50:264–70. This study describes characteristics of individuals with inherited mutations in CDK4. The authors note that germline CDK4 mutations are rare. They conclude that the phenotype of individuals with inherited CDK4 mutations, which includes younger than average age of melanoma onset, multiple primary melanomas, multiple relatives with melanoma, and relatives with pancreatic cancer, is similar to the phenotype of individuals with CDKN2A germline mutations.PubMedCentralPubMedCrossRef
27.
Cust A, Goumas C, Vuong K, Davies J, Barrett J, Holland E, et al. MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study. BMC Cancer. 2013;4:406.CrossRef
28.
Mitra D, Luo X, Morgan A, Wang J, Hoang M, Lo J, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012;491:449–53.PubMedCentralPubMedCrossRef
29.
Begg C, Orlow I, Hummer A, Armstrong B, Kricker A, Marrett L, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. 2005;97:1507–15.
30.••
Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, et al. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family. J Am Acad Dermatol. 2012;67:1257–64. This study examines the correlation between the number of relatives affected with melanoma and CDKN2A mutation status in a French cohort. In the context of the study, the authors also review the features associated with CDKN2A mutation status. The results of this study reveal that a greater number of relatives with melanoma correlate to a higher probability of having a germline CDKN2A mutation.PubMedCrossRef
31.
Tsao H, Zhang X, Kwitkiwski L, Finkelstein D, Sober A, Haluska F. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol. 2000;136:1118–22.PubMedCrossRef
32.
Pedace L, De Simone P, Castori M, Sperduti I, Silipo V, Eibenschutz L, et al. Clinical features predicting identification of CDKN2A mutations in Italian patients with familial cutaneous melanoma. Cancer Epidemiol. 2011;35:e116–20.PubMedCrossRef
33.
Blackwood MA, Holmes R, Synnestvedt M, Young M, George C, Yang H, et al. Multiple primary melanoma revisited. Cancer. 2002;94:2248–55.PubMedCrossRef
34.
Monzon J, Liu L, Brill H, Goldstein A, Tucker M, From L, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338:879–87.PubMedCrossRef
35.
Nikolaou V, Kang X, Stratigos A, Gogas H, Latorre MC, Gabree M, et al. Comprehensive mutational analysis of CDKN2A and CDK4 in Greek patients with cutaneous melanoma. Br J Dermatol. 2011;165:1219–22.PubMedCentralPubMedCrossRef
36.
Whiteman D, Milligan A, Welch J, Green A, Hayward N. Germline CDKN2A mutations in childhood melanoma. JNCI. 1997;89(19):1460.PubMedCrossRef
37.
Berg P, Wennberg A-M, Tuominen R, Sander B, Rozell B, Platz A, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. Melanoma Res. 2004;14(4):251–5.PubMedCrossRef
38.
de Snoo F, Bishop DT, Bergman B, van Leeuwen I, van der Drift C, van Nieuwpoort F, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008;14:7151–7.PubMedCrossRef
39.
Harinck F, Kluijt I, van der Stoep N, Oldenburg R, Wagner A, Aalfs C, et al. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. J Med Genet. 2012;49:362–5.PubMedCrossRef
40.
Ghiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. J Med Genet. 2012;49:164–70.PubMedCrossRef
41.
McWilliams R, Wieben E, Rabe K, Pedersen K, Wu Y, Sicotte H, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2010;19:472–8.PubMedCentralPubMedCrossRef
42.
Tucker M, Fraser M, Goldstein A, Struewing J, King M, Crawford J, et al. A natural history of melanomas and dysplastic nevi. Cancer. 2002;94:3192–209.PubMedCrossRef
43.
Goldstein A, Martinez M, Tucker M, Demenais F. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomarkers Prev. 2000;9:889–94.PubMed
44.
Hussussian C, Struewing J, Goldstein A, Higgins P, Ally D, Sheahan M, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8(1):15–21.PubMedCrossRef
45.
American Society of Clinical Oncology policy statement update. Genetic testing for cancer susceptibility. J Clin Oncol. 2003;21(12):2397–406.CrossRef
46.
Robson M, Storm C, Weitzel J, Wollins D, Offit K. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893–901.PubMedCrossRef
47.
Kefford R, Newton Bishop J, Bergman W, Tucker M. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the melanoma consortium. J Clin Oncol. 1999;17(10):3245–51.PubMed
48.
Demenais F, Mohamdi H, Chaudru V, Goldstein A, Bishop J, Bishop D, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010;102:1568–83.PubMedCentralPubMedCrossRef
49.
Gerstenblith M, Goldstein A, Tucker M, Fraser M. Genetic testing for melanoma predisposition: current challenges. Cancer Nurs. 2007;30(6):454–61.CrossRef
50.
Hansen C, Wadge L, Lowstuter K, Boucher K, Leachman S. Clinical germline genetic testing for melanoma. Lancet. 2004;5:314–9.CrossRef
51.
de Snoo F, Bergman W, Gruis N. Familial melanoma: a complex disorder leading to controversy on DNA testing. Familial Cancer. 2003;2:109–16.PubMedCrossRef
52.
Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, Grumet S, et al. Genetic cancer risk assessment and counseling: recommendation of the National Society of Genetic Counselors. J Genet Couns. 2004;13(2):83–114.PubMedCrossRef
53.
Gomy I, Diz M. Hereditary cancer risk assessment: essential tools for a better approach. Hered Cancer Clin Pract. 2013;11(16):1–8.
54.
Weitzel J, Blazer K, MacDonald D, Culver J, Offit K. Genetics, genomics, and cancer risk assessment. CA Cancer J Clin. 2011;61:327–59.
55.
Caini S, Gandini S, Sera F, Raimondi S, Fargnoli M, Boniol M, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer. 2009;45:3054–63.PubMedCrossRef
56.
Wang W, Niendorf K, Patel D, Blackford A, Marroni F, Sober A, et al. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPro. Cancer Res. 2010;70(2):552–9.PubMedCentralPubMedCrossRef
57.
Tsao H, Niendorf K. Genetic testing in hereditary melanoma. J Am Acad Dermatol. 2004;51(5):803–8.PubMedCrossRef
58.
Canto M, Harinck F, Hruban R, Offerhaus G, Poley J, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.PubMedCentralPubMedCrossRef
59.
60.•
Champine M, Kohlmann W, Leachman S. Genetic counseling and testing for hereditary melanoma: an updated guide for dermatologists. Genetics. 2013;S2:004. This article provides a summary of factors associated with melanoma risk assessment including environmental exposure, phenotype, and genetic status. They also discuss the process of genetic counseling and testing for CDKN2A.
61.
62.
Domchek S, Bradbury A, Garber J, Offit K, Robson M. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31:1267–70.PubMedCrossRef
63.•
Aspinwall L, Taber J, Leaf S, Kohlmann W, Leachman S. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. Cancer Epidemiol Biomarkers Prev. 2013;22:1687–97. This study assesses the long term effect of CDNK2A genetic counseling and testing on the adherence to clinical and self skin examinations. The results of this study show increased adherence to clinical and self skin examinations in unaffected CDKN2A mutation carriers. The authors conclude that these findings suggest a benefit to genetic counseling and testing for CDKN2A in unaffected relatives of CDKN2A mutation carriers.PubMedCrossRef
64.
de Snoo F, Riedijk S, van Mil A, Bergman W, ter Huurne J, Timman R, et al. Genetic testing in familial melanoma: uptake and implications. Psychooncology. 2008;17:790–6.PubMedCrossRef
65.
Glanz K, Volpicelli K, Kanetsky PA, Ming ME, Schuchter LM, Jepson C, et al. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Cancer Epidemiol Biomarkers Prev. 2013;22:607–14.PubMedCentralPubMedCrossRef
66.
Aspinwall L, Leaf S, Dola R, Kohlmann W, Leachman S. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. J Am Acad Dermatol. 2009;60:745–57.PubMedCrossRef
Metadaten
Titel
Clinical Applications of Melanoma Genetics
verfasst von
Michele Gabree, MS
Devanshi Patel, MS
Linda Rodgers, MGC
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Current Treatment Options in Oncology / Ausgabe 2/2014
Print ISSN: 1527-2729
Elektronische ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-014-0282-8

Weitere Artikel der Ausgabe 2/2014

Current Treatment Options in Oncology 2/2014 Zur Ausgabe

Leukemia (JP Dutcher, Section Editor)

New Approaches to Management of Multiple Myeloma

Skin Cancer (WH Sharfman, Section Editor)

What Is the Role of Chemotherapy in the Treatment of Melanoma?

Lymphoma (A Engert, Section Editor)

Role of CD30 Targeting in Malignant Lymphoma

Leukemia (JP Dutcher, Section Editor)

Optimal Therapy for Adult Patients with Acute Myeloid Leukemia in First Complete Remission

Lymphoma (A Engert, Section Editor)

Radiotherapy of Follicular Lymphoma: Updated Role and New Rules

Skin Cancer (WH Sharfman, Section Editor)

Update on Vaccines for High-Risk Melanoma

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Beim Melanom könnte „Operation zuerst“ zum Auslaufmodell werden

03.06.2024 ASCO 2024 Kongressbericht

Nicht nur besser, auch viel kürzer: Die neoadjuvante Melanom-Therapie mit Checkpoint-Inhibitoren beeindruckt in der Erstauswertung der NADINA-Studie. Sie könnte ein neuer Standard werden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise